Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258440 · ClinicalTrials.gov registry record · NA
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
A NA study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00258440 is a NA study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT00258440, a NA study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia. PURPOSE: This randomized clinical trial is studying how well epoetin alfa works in treating patients with anemia who are undergoing chemotherapy for cancer.
Interventions
- DRUG Weekly procrit dosing
- DRUG Interval Dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2003-05 |
| Est. Completion | 2008-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258440
The ClinicalTrials.gov registry entry for NCT00258440 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Weekly procrit dosing is the first listed.
NCT00258440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258440 about?
NCT00258440 is a clinical study titled "Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer". RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia. PURPOSE: This randomized clinical trial is studying how well epoetin alfa works in treating patients with ...
What is the current status of trial NCT00258440?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2003-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00258440?
The interventions under investigation include: Weekly procrit dosing (DRUG), Interval Dosing (DRUG).
Who is sponsoring clinical trial NCT00258440?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.